DarioHealth price target lowered to $4.10 from $5.45 at Alliance Global

Alliance Global Partners lowered the firm’s price target on DarioHealth to $4.10 from $5.45 and keeps a Buy rating on the shares. The company reported “mixed” Q2 results and the target drop is entirely driven by reduced sales estimates, the analyst tells investors in a research note. While Dario management shared color on numerous customer wins and strategic partnerships, the impact of these positive developments have not materialized in reported numbers, the analyst tells investors in a research note.